Novel mechanism of aryl hydrocarbon receptor - mediated differential gene regulation
芳烃受体介导差异基因调控的新机制
基本信息
- 批准号:10291689
- 负责人:
- 金额:$ 14.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-12 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
ABSTRACT
Aryl hydrocarbon Receptor (AhR), a mediator of xenobiotic toxicity, is known to function as a ligand-activated
transcription factor that binds to a xenobiotic response element (XRE, GCGTG motif) in association with its
heterodimerization partner, the AhR nuclear translocator (Arnt) protein. This proposal is built on our
observation that cinnabarinic acid (CA) mediated AhR-dependent induction of stanniocalcin 2 (stc2) attenuates
stress induced apoptosis and protects against liver injury both in vitro and in vivo. stc2 induction was achieved
in response to endogenous AhR agonist CA but not the classic exogenous AhR ligand 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). Moreover, CA in contrast to TCDD, was unable to trigger prototypical AhR
target gene, cyp1a1 in hepatocytes and did not regulate xenobiotic metabolism. Therefore, stc2 and cyp1a1
genes exhibit mutually exclusive agonist-specific AhR-mediated transcriptional responsiveness with distinct
physiological consequences. As a part of my K01 research, we observed interaction of Metastasis-associated
protein 2 (MTA2), a known chromatin remodeling protein, with AhR exclusively upon CA treatment. AhR-MTA2
complex was recruited only to stc2, but not cyp1a1 promoter. In addition, CA treatment was able to exhibit
histone H4 lysine 5 acetylation specifically at stc2 promoter concomitant with AhR-MTA2 complex recruitment.
Our preliminary studies identified that chromatin architecture in addition to the primary DNA sequence
significantly contributes to the agonist-specific differential gene expression. Building on our preliminary studies
this proposal tests the hypothesis that CA-specific AhR-dependent epigenetic modifications and chromatin
restructuring dictates transcription regulation of stc2, which in turn is responsible for cytoprotection following
liver injury. Specific Aim 1 of this application will profile CA and TCDD specific epigenetic modifications as well
as will identify the readers-writers-erasers of the histone modifications recruited to the XRE bounds AhR-MTA2
complex. Specific Aim 2 will determine role of chromatin architecture in agonist specific stc2 regulation by
using CRISPR/Cas9 gene editing. Specific Aim 3 will interrogate mechanism by which CA-triggered stc2
protects against ethanol-induced apoptosis by identifying downstream cytoprotective pathway components
activated by stc2. Therefore, the objective of this application is to decode CA-specific AhR-mediated
transcription regulation of stc2 and decipher its cytoprotective function. Given stc2’s involvement in
cytoprotection against liver injury, understanding its CA-specific regulation may serve as a key to developing
future molecular therapeutics targeting hepatic diseases.
摘要
芳香烃受体(AhR)是异种生物毒性的媒介,被认为是一种配体激活的功能。
与异源反应元件结合的转录因子(XRE,GCGTG基序)与其相关
异二聚化伙伴,AhR核转运子(ARNT)蛋白。这项建议是建立在我们的
桂皮酸(CA)介导的AhR依赖的锡钙素2(Stc2)诱导减弱的观察
应激在体外和体内均可诱导细胞凋亡并保护肝损伤。获得了stc2诱导
对内源性AhR激动剂CA而不是经典的外源性AhR配体2,3,7,8-
四氯二苯并对二恶英(TCDD)此外,与TCDD相比,CA不能触发原型AhR
靶基因cyp1a1在肝细胞中表达,不调节异种代谢。因此,stc2和cyp1a1
基因表现出相互排斥的激动剂特异性AhR介导的转录反应,具有不同的
生理后果。作为我K01研究的一部分,我们观察到与转移相关的相互作用
蛋白2(MTA2),一种已知的染色质重塑蛋白,其AhR仅适用于CA处理。AHR-MTA2
复合体只与stc2启动子结合,而不与cyp1a1启动子结合。此外,CA治疗能够表现出
组蛋白H4赖氨酸5在stc2启动子上的乙酰化伴随着AhR-MTA2复合体的招募。
我们的初步研究证实,除了初级DNA序列外,染色质的结构
显著促进了激动剂特异性差异基因的表达。以我们的初步研究为基础
这一建议检验了CA特异性AhR依赖的表观遗传修饰和染色质的假设
重组决定了stc2的转录调控,而stc2又负责以下的细胞保护
肝脏损伤。本申请的特定目标1也将描述CA和TCDD特定的表观遗传修饰
AS将识别招募到XRE边界AhR-MTA2的组蛋白修饰的读取器-写入器-擦除器
很复杂。特异性目标2将通过以下方式确定染色质结构在激动剂特异性stc2调节中的作用
使用CRISPR/Cas9基因编辑。特定目标3将询问CA触发stc2的机制
识别下游细胞保护通路成分对乙醇诱导的细胞凋亡的保护作用
由stc2激活。因此,此应用程序的目标是解码CA特定的AhR中介
Stc2的转录调控并破译其细胞保护功能。鉴于STC2的S参与了
对肝损伤的细胞保护,了解其CA特异性调节可能是发展的关键
针对肝病的未来分子治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aditya D Joshi其他文献
Aditya D Joshi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aditya D Joshi', 18)}}的其他基金
Novel Mechanism of aryl hydrocarbon receptor-mediated differential gene regulation
芳烃受体介导的差异基因调控新机制
- 批准号:
9976506 - 财政年份:2019
- 资助金额:
$ 14.81万 - 项目类别:
Novel Mechanism of aryl hydrocarbon receptor-mediated differential gene regulation
芳烃受体介导的差异基因调控新机制
- 批准号:
9802904 - 财政年份:2019
- 资助金额:
$ 14.81万 - 项目类别:
Novel mechanism of aryl hydrocarbon receptor - mediated differential gene regulation
芳烃受体介导差异基因调控的新机制
- 批准号:
10612044 - 财政年份:2019
- 资助金额:
$ 14.81万 - 项目类别:
Novel mechanism of aryl hydrocarbon receptor - mediated differential gene regulation
芳烃受体介导差异基因调控的新机制
- 批准号:
10399477 - 财政年份:2019
- 资助金额:
$ 14.81万 - 项目类别:
Characterization of cinnabarinic acid mediated cytoprotection upon liver injury
朱砂酸介导的肝损伤细胞保护作用的表征
- 批准号:
9146345 - 财政年份:2015
- 资助金额:
$ 14.81万 - 项目类别:
相似国自然基金
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
- 批准号:82371634
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
- 批准号:82371332
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
- 批准号:82371651
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
- 批准号:82370798
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
慢性炎症诱发骨丢失的机制及外泌体靶向治疗策略研究
- 批准号:82370889
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
5'-tRF-GlyGCC通过SRSF1调控RNA可变剪切促三阴性乳腺癌作用机制及干预策略
- 批准号:82372743
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
TIPE2调控巨噬细胞M2极化改善睑板腺功能障碍的作用机制研究
- 批准号:82371028
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
骨髓ISG+NAMPT+中性粒细胞介导抗磷脂综合征B细胞异常活化的机制研究
- 批准号:82371799
- 批准年份:2023
- 资助金额:47.00 万元
- 项目类别:面上项目
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
- 批准号:82371616
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
超声驱动压电效应激活门控离子通道促眼眶膜内成骨的作用及机制研究
- 批准号:82371103
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
相似海外基金
Novel Mechanism of aryl hydrocarbon receptor-mediated differential gene regulation
芳烃受体介导的差异基因调控新机制
- 批准号:
9976506 - 财政年份:2019
- 资助金额:
$ 14.81万 - 项目类别:
Novel Mechanism of aryl hydrocarbon receptor-mediated differential gene regulation
芳烃受体介导的差异基因调控新机制
- 批准号:
9802904 - 财政年份:2019
- 资助金额:
$ 14.81万 - 项目类别:
Novel mechanism of aryl hydrocarbon receptor - mediated differential gene regulation
芳烃受体介导差异基因调控的新机制
- 批准号:
10612044 - 财政年份:2019
- 资助金额:
$ 14.81万 - 项目类别:
Novel mechanism of aryl hydrocarbon receptor - mediated differential gene regulation
芳烃受体介导差异基因调控的新机制
- 批准号:
10399477 - 财政年份:2019
- 资助金额:
$ 14.81万 - 项目类别:
A novel mechanism of gene-environment interaction in autoimmune arthritis
自身免疫性关节炎基因-环境相互作用的新机制
- 批准号:
8768943 - 财政年份:2014
- 资助金额:
$ 14.81万 - 项目类别:
A novel mechanism of gene-environment interaction in autoimmune arthritis
自身免疫性关节炎基因-环境相互作用的新机制
- 批准号:
8898805 - 财政年份:2014
- 资助金额:
$ 14.81万 - 项目类别:
A Novel mechanism for Environmentally Induced Airway Disease
环境诱发气道疾病的新机制
- 批准号:
8818368 - 财政年份:2014
- 资助金额:
$ 14.81万 - 项目类别:
A Novel mechanism for Environmentally Induced Airway Disease
环境诱发气道疾病的新机制
- 批准号:
9185978 - 财政年份:2014
- 资助金额:
$ 14.81万 - 项目类别:
A Novel mechanism for Environmentally Induced Airway Disease
环境诱发气道疾病的新机制
- 批准号:
8976608 - 财政年份:2014
- 资助金额:
$ 14.81万 - 项目类别:
Research on The Novel Photo-rearrangement And Photo-fragmentation of Arylated Cyclic Peroxides
芳基化环状过氧化物新型光重排和光裂解研究
- 批准号:
09640629 - 财政年份:1997
- 资助金额:
$ 14.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




